Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Adult and Child Center for Health Outcomes Research and Delivery Science (ACCORDS), University of Colorado School of Medicine/Children's Hospital Colorado, Aurora, CO, USA.
Hum Vaccin Immunother. 2022 Nov 30;18(6):2146434. doi: 10.1080/21645515.2022.2146434. Epub 2022 Nov 20.
The American Academy of Pediatrics (AAP) recommends starting the human papillomavirus (HPV) vaccine series between 9 and 12 years, at an age that the provider deems optimal for acceptance and completion of the vaccination series. This recommendation differs from the Advisory Committee on Immunization Practices (ACIP), which recommends HPV vaccination be initiated at age 11 or 12 years, stating the series can be started at age 9 years. This commentary discusses the reasoning behind AAP's decision to differ from ACIP, as the AAP and ACIP schedules are essentially harmonized for all other vaccines. Reasons include recognition that (1) vaccination uptake is suboptimal; (2) offering vaccination earlier offers provider's flexibility in introducing the vaccine; (3) initiating the vaccine at age 9 or 10 may be preferable for parents or adolescents who do not want to receive ≥3 concomitant vaccines at age 11 or 12; (4) earlier initiation may disentangle HPV recommendations from discussions of sexuality; (5) earlier recommendation might alleviate HPV vaccine hesitancy "fatigue;" (6) the immune response is robust at younger ages with no evidence of waning protection; and (7) there is a dearth of evidence supporting starting the recommendation at age 11 or 12 within the "adolescent immunization platform."
美国儿科学会(AAP)建议在 9 至 12 岁之间开始接种人乳头瘤病毒(HPV)疫苗系列,这个年龄段被认为是接受和完成疫苗系列接种的最佳时期。这一建议与免疫实践咨询委员会(ACIP)不同,后者建议 HPV 疫苗接种应在 11 或 12 岁开始,并指出该疫苗系列可以在 9 岁开始接种。本评论讨论了 AAP 决定与 ACIP 不同的原因,因为 AAP 和 ACIP 的时间表在所有其他疫苗方面基本一致。原因包括认识到 (1) 疫苗接种率不理想;(2) 提前接种为提供者提供了引入疫苗的灵活性;(3) 对于不想在 11 或 12 岁时同时接种≥3 种疫苗的家长或青少年来说,在 9 或 10 岁开始接种可能更为理想;(4) 更早的接种可能将 HPV 建议与性行为讨论分开;(5) 更早的建议可能减轻 HPV 疫苗犹豫“疲劳”;(6) 免疫反应在较年轻时非常强烈,没有证据表明保护作用减弱;(7) 在“青少年免疫平台”内,几乎没有证据支持在 11 或 12 岁开始推荐接种疫苗。